Procalcitonin is not a reliable biomarker of bacterial coinfection in people with coronavirus disease 2019 undergoing microbiological investigation at the time of hospital admission

Relph, K. A. et al. (2022) Procalcitonin is not a reliable biomarker of bacterial coinfection in people with coronavirus disease 2019 undergoing microbiological investigation at the time of hospital admission. Open Forum Infectious Diseases, 9(5), ofac179. (doi: 10.1093/ofid/ofac179) (PMID:35531376) (PMCID:PMC9070482)

[img] Text
268122.pdf - Published Version
Available under License Creative Commons Attribution.



Admission procalcitonin measurements and microbiology results were available for 1040 hospitalized adults with coronavirus disease 2019 (from 48 902 included in the International Severe Acute Respiratory and Emerging Infections Consortium World Health Organization Clinical Characterisation Protocol UK study). Although procalcitonin was higher in bacterial coinfection, this was neither clinically significant (median [IQR], 0.33 [0.11–1.70] ng/mL vs 0.24 [0.10–0.90] ng/mL) nor diagnostically useful (area under the receiver operating characteristic curve, 0.56 [95% confidence interval, .51–.60]).

Item Type:Articles
Additional Information:Christopher Davis is a member of the ISARIC4C Investigators, This work was supported by the National Institute for Health Research (NIHR) [grant number CO-CIN-01], the Medical Research Council [grant number MC_PC_19059] and by the NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford [grant number 200907], NIHR HPRU in Respiratory Infections at Imperial College London with PHE [grant number 200927], Wellcome Trust and Department for International Development [grant number 215091/Z/18/Z], and the Bill and Melinda Gates Foundation [grant number OPP1209135], and Liverpool Experimental Cancer Medicine Centre (grant number C18616/A25153), NIHR Biomedical Research Centre at Imperial College London [grant number IS-BRC3 1215-20013], EU Platform for European Preparedness Against (Re-) emerging Epidemics (PREPARE) [FP7 project 602525] and NIHR Clinical Research Network for providing infrastructure support for this research. LT is supported by a Wellcome Trust fellowship [grant number 205228/Z/16/Z]. PJMO is supported by a NIHR Senior Investigator Award [grant number 201385].
Glasgow Author(s) Enlighten ID:Davis, Dr Chris and Ho, Dr Antonia
Authors: Relph, K. A., Russell, C. D., Fairfield, C. J., Turtle, L., de Silva, T. I., Siggins, M. K., Drake, T. M., Thwaites, R. S., Abrams, S., Moore, S. C., Hardwick, H. E., Oosthuyzen, W., Harrison, E. M., Docherty, A. B., Openshaw, P. J.M., Baillie, K., Semple, M. G., Ho, A., and ISARIC4C investigators,
College/School:College of Medical Veterinary and Life Sciences > School of Infection & Immunity > Centre for Virus Research
Journal Name:Open Forum Infectious Diseases
Publisher:Oxford University Press
ISSN (Online):2328-8957
Published Online:01 May 2022
Copyright Holders:Copyright © 2022 The Author(s)
First Published:First published in Open Forum Infectious Diseases 9(5): ofac179
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
310665ISARIC - Coronavirus Clinical Characterisation ConsortiumAntonia HoMedical Research Council (MRC)MC_PC_19059 - 9815274III - Centre for Virus Research